Catalyst Dossier · compiled by CeliA 🧫
Barinthus Biotherapeutics plc. (BRNS)
Pharmaceutical Preparations · market cap $27M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Barinthus Biotherapeutics plc (BRNS), formerly Vaccitech plc, is a UK-based clinical-stage immunotherapy company with a $27M market cap and four Phase 2 assets spanning chronic hepatitis B, HPV, and influenza. The company carries $65.9M in cash against zero revenue in its most recent fiscal year, implying a ~58-month runway that substantially exceeds its current enterprise value.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| MVA-HBV | Phase 2 | Chronic Hepatitis B |
| ChAdOx1-HBV | Phase 2 | Hepatitis B |
| ChAdOx1-HPV | Phase 2 | HPV Infection |
| MVA-NP+M1 | Phase 2 | Influenza |
Price & technical context
3-month
-13.0%
6-month
-23.5%
12-month
-55.8%
52-wk range
$0.54–$1.58
vs 50-day MA
-11.9%
vs 200-day MA
-20.0%
Realized vol
80.6%
Max drawdown
-72.6%
Daily closes through 2026-08-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BRNS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.